Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso

Introduction: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV ser...

Full description

Saved in:

Bibliographic Details
Published in:	Intervirology Vol. 65; no. 3; pp. 151 - 159
Main Authors:	Yelemkoure, Edwige T., Yonli, Albert T., Sombie, Hermann K., Tao, Issoufou, Zouré, Abdou Azaque, Ouattara, Abdoul Karim, Sorgho, Abel P., Zongo, Arsène W., Zeba, Moctar T.A., Kiendrebeogo, Isabelle T., Bado, Prosper, Kabré, Madeleine K., Zohoncon, Théodora M., Djigma, Florencia W., Obiri-Yeboah, Dorcas, Simpore, Jacques
Format:	Journal Article
Language:	English
Published:	Basel, Switzerland S. Karger AG 01-07-2022 Karger Publishers
Subjects:	Antibodies Antiviral agents Care and treatment Health aspects Hepatitis C virus Liver cirrhosis Planning Research Article Viral antibodies Burkina Faso Genotype Pan-genotypic drugs Burkina Faso Hepatitis C virus Viral load
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Introduction: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV seroprevalence, characterize circulating genotypes, and monitor HCV viral loads in patients under treatment with antivirals. Methods: A total of 4,124 individuals and 167 patients in the pre-therapy program were recruited. The “SD Bioline HCV” kit was used for rapid screening of anti-HCV antibodies. Viral load and genotyping were performed in 167 HCV patients on antivirals using the “Iontek HCV Quant” and “Iontek genotyping” kits. Results: Prevalence of HCV was 1.65% (68/4,124), and the median viral load of participants was 5.37 log10/mL (1.32–7.67 log10/mL). Genotype 2 was predominant with a frequency of 86.23% (144/167) and appeared to be more active with higher viral load compared to 13.77% (23/167) for genotype 1 (p < 0.001). After 24 weeks of pan-genotypic direct-acting antivirals, such as sofosbuvir/daclatasvir and sofosbuvir/velpatasvir, the viral loads of all patients became undetectable. Conclusion: The responses to antivirals by the circulating genotypes indicate that the results are very satisfactory. Therefore, the prevalence of HCV in the population can be reduced through identification of cases and treatment.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0300-5526 1423-0100
DOI:	10.1159/000519848